申请人:UNION therapeutics A/S
公开号:US10758553B2
公开(公告)日:2020-09-01
The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.
本发明涉及一种卤代水杨酰苯胺,选自closingantel、rafoxanide、oxyclozanide和niclosamide及其衍生物,包括盐类、水合物、酯类等,用于局部治疗或预防革兰氏阳性菌如葡萄球菌,特别是金黄色葡萄球菌和链球菌,特别是化脓性链球菌引起的感染。与常用的局部抗生素相比,使用卤代水杨酰苯胺处理的革兰氏阳性细菌出现抗药性突变体的频率非常低。